Related Experiment Video
Updated: Jun 25, 2025

Chromosome Preparation From Cultured Cells
Published on: January 28, 2014
Chromothripsis in myeloid malignancies
1Department of Internal Medicine, Division of Hematology, National Taiwan University Hospital, No. 7, Chung-Shan South Road, Taipei, 100, Taiwan. chienyuanchen@ntu.edu.tw.
Chromothripsis, a major genomic rearrangement, occurs in various cancers like acute myeloid leukemia (AML). Patients with chromothripsis often face poorer prognoses and lower remission rates, necessitating further research.
Area of Science:
- Genomics
- Cancer Biology
- Hematology
Background:
- Chromothripsis involves massive genomic rearrangements during a single catastrophic event.
- It is observed in various malignancies, including acute myeloid leukemia (AML) and myelodysplastic syndrome (MDS).
- Incidence varies significantly based on malignancy type and specific genetic mutations, such as TP53.
Purpose of the Study:
- To summarize the incidence, associated genetic factors, and clinical implications of chromothripsis in myeloid malignancies.
- To highlight the prognostic impact of chromothripsis on treatment response and survival rates.
Main Methods:
- Review of existing literature on chromothripsis in AML and MDS.
- Analysis of reported incidences, genetic associations (e.g., TP53, ERG, FLT3, NPM1), and clinical outcomes.
Main Results:
- Chromothripsis incidence ranges widely: 0-6.6% in AML, 27.3-100% in complex karyotype AML, 11.1-90% in AML with TP53 mutations.
- Associated with complex karyotypes, TP53 mutations, and monosomal karyotypes; ERG amplifications are frequent, MYC amplifications are not.
- Negatively associated with FLT3 and NPM1 mutations; typically occurs in older AML patients with low leukocyte and blast counts.
- Associated with poor prognosis, including lower complete remission rates and worse overall survival in myeloid malignancies.
- Signal pathways involve oncogene upregulation and tumor suppressor downregulation.
Conclusions:
- Chromothripsis is linked to adverse outcomes in myeloid malignancies.
- Further large-scale studies are crucial to understand its causes and develop targeted treatments.
Related Concept Videos
Abnormal Proliferation
Separation of Sister Chromatids
At the onset of anaphase, separase, a proteolytic enzyme, is...
Restarting Stalled Replication Forks
Anaphase Promoting Complex
Inheritance of Chromatin Structures
Cancers Originate from Somatic Mutations in a Single Cell

